Compound Shows Promise in Halting Huntington's Disease
A new study offers a potential breakthrough in the fight against Huntington's disease, a devastating genetic disorder that progressively destroys brain cells. Researchers have found that a compound called anle138b can significantly reduce toxic protein clumps in the brain, leading to improved mobility and extended lifespan in animal models.
The research, published in EMBO Molecular Medicine, tested the compound in two distinct mouse models of the disease.
In both models, treated mice retained mobility, had less brain shrinkage, and lived longer than untreated mice.
One model represented a severe, early-onset form of the disease, while the other mirrored the more common adult-onset form. Remarkably, the compound produced positive results in both cases. The effects were further validated in human stem cells derived from Huntington's patients, where levels of harmful protein aggregates were reduced.
How the Compound Works
Huntington's disease is caused by a specific genetic defect—repeated CAG segments in the huntingtin gene. This defect causes the huntingtin protein to misfold and clump together inside neurons, forming toxic aggregates that disrupt communication and trigger cell death. This damage is concentrated in brain regions responsible for movement and cognition.
Anle138b targets this fundamental problem at its source.
"Anle138b prevents the formation of these harmful protein structures. The study shows that targeting aggregation with this compound is a promising approach to stabilize neuronal health."
By blocking the formation of these aggregates, the compound appears to protect neurons from damage, preserving their function and delaying the onset of symptoms.
A Key Biomarker Confirms Protection
Researchers also examined a well-known early marker of Huntington's disease: the loss of a protein called PDE10A. As the disease progresses, PDE10A levels drop, signaling neuronal death.
In both mouse models, anle138b treatment kept PDE10A levels high, indicating reduced neuronal death.
This biomarker evidence provides strong, measurable proof that the compound is effectively protecting brain cells from the disease's ravages.
Broader Implications and Next Steps
The study was led by Professor Irina Dudanova and doctoral student Miguel da Silva Padilha at the University of Würzburg. The anle138b compound was originally developed by Christian Griesinger at the Max Planck Institute for Multidisciplinary Sciences and Armin Giese, formerly of LMU Munich and now with MODAG GmbH.
Because the compound targets a fundamental mechanism of protein aggregation found in many neurodegenerative diseases, its potential extends beyond Huntington's. A clinical trial for multiple system atrophy (MSA)—a Parkinson's-like disorder—was launched two years ago, and research into other conditions is ongoing.
This breakthrough suggests that a single strategy, aimed at stopping toxic protein clumps, could provide a powerful new weapon against some of the most challenging neurological diseases.